Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5278284
Max Phase: Preclinical
Molecular Formula: C61H69N9O9S
Molecular Weight: 1104.34
Associated Items:
ID: ALA5278284
Max Phase: Preclinical
Molecular Formula: C61H69N9O9S
Molecular Weight: 1104.34
Associated Items:
Canonical SMILES: Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@H](O)CN2C(=O)[C@H](C(C)C)N2Cc3ccccc3C2=O)c(OCCNC(=O)c2ccccc2NC(=O)[C@H](CCCCN)NC(=O)[C@@H]2CCCN2C(=O)Cc2cccc3ccccc23)c1
Standard InChI: InChI=1S/C61H69N9O9S/c1-37(2)54(70-34-43-15-5-7-19-46(43)60(70)77)61(78)69-35-44(71)32-51(69)58(75)64-33-42-25-24-41(55-38(3)65-36-80-55)30-52(42)79-29-27-63-56(73)47-20-8-9-21-48(47)66-57(74)49(22-10-11-26-62)67-59(76)50-23-13-28-68(50)53(72)31-40-17-12-16-39-14-4-6-18-45(39)40/h4-9,12,14-21,24-25,30,36-37,44,49-51,54,71H,10-11,13,22-23,26-29,31-35,62H2,1-3H3,(H,63,73)(H,64,75)(H,66,74)(H,67,76)/t44-,49-,50-,51-,54-/m0/s1
Standard InChI Key: CHPPXVHKCHZTIK-VQJUJIIGSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1104.34 | Molecular Weight (Monoisotopic): 1103.4939 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Zhou Q, Wu W, Jia K, Qi G, Sun XS, Li P.. (2022) Design and characterization of PROTAC degraders specific to protein N-terminal methyltransferase 1., 244 [PMID:36228414] [10.1016/j.ejmech.2022.114830] |
Source(1):